Scavenger protein receptor aids the transport of lipoproteins
Lipoproteins are spherical molecules made up of fat and proteins that play a crucial role in transporting lipids, such as cholesterol and triglycerides, from the liver to other tissues in the body. Anton Potapenko of the University of Zurich, and a team in Switzerland recently published a study in the Journal of Lipid Research detailing structural characteristics of the scavenger receptor B1, or SCARB1, a protein that mediates lipid exchange between many cell types and facilitates uptake of high density lipoproteins, or HDL, and low density lipoproteins, or LDL, in some cell types. The gene encoding SCARB1 produces two major splice variants that share structural similarities but differ in their carboxy-terminal domains. Researchers wanted to understand if these splice variants play different roles in the cellular uptake of LDL and HDL by endothelial cells.

The researchers examined cultured endothelial cells to understand how expression of the two SCARB1 variants affected the binding, uptake and trafficking of lipoproteins. They found that variants 1 and 2 localized to the cell surface, and endosomes and lysosomes, respectively. Overexpression of variant 1 increased both HDL and LDL binding and uptake. However, overexpression of variant 2 also increased the uptake of either lipoprotein, but not via surface binding. Therefore, the researchers concluded that variant 2 facilitates lipoprotein uptake indirectly by regulatory and indirect mechanisms.
The study suggests that the two major splice variants of SCARB1 facilitate transendothelial transport of HDL and LDL by different mechanisms, either dependent or independent of the adapter proteins. Because of the limitations of overexpression, it will be important to examine how eliminating each SCARB1 splice variant affects cellular lipid metabolism and lipoprotein trafficking.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.